- Home
- USCB vs CDXC Comparison
USCB vs CDXC Comparison
Compare USCB & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- CDXC
- Stock Information
- Founded
- USCB 2002
- CDXC 1999
- Country
- USCB United States
- CDXC United States
- Employees
- USCB N/A
- CDXC N/A
- Industry
- USCB Major Banks
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- USCB Finance
- CDXC Health Care
- Exchange
- USCB Nasdaq
- CDXC Nasdaq
- Market Cap
- USCB 353.0M
- CDXC 415.5M
- IPO Year
- USCB 2021
- CDXC N/A
- Fundamental
- Price
- USCB $18.20
- CDXC $5.94
- Analyst Decision
- USCB Buy
- CDXC Strong Buy
- Analyst Count
- USCB 4
- CDXC 2
- Target Price
- USCB $16.13
- CDXC $8.00
- AVG Volume (30 Days)
- USCB 26.6K
- CDXC 458.5K
- Earning Date
- USCB 01-23-2025
- CDXC 03-05-2025
- Dividend Yield
- USCB 1.10%
- CDXC N/A
- EPS Growth
- USCB 13.14
- CDXC N/A
- EPS
- USCB 1.04
- CDXC 0.02
- Revenue
- USCB $71,791,000.00
- CDXC $91,668,000.00
- Revenue This Year
- USCB N/A
- CDXC $18.64
- Revenue Next Year
- USCB $15.26
- CDXC $20.72
- P/E Ratio
- USCB $17.49
- CDXC $306.20
- Revenue Growth
- USCB 10.04
- CDXC 9.95
- 52 Week Low
- USCB $10.25
- CDXC $1.36
- 52 Week High
- USCB $21.86
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- USCB 53.16
- CDXC 54.82
- Support Level
- USCB $16.01
- CDXC $5.17
- Resistance Level
- USCB $18.42
- CDXC $5.52
- Average True Range (ATR)
- USCB 0.64
- CDXC 0.26
- MACD
- USCB 0.11
- CDXC 0.08
- Stochastic Oscillator
- USCB 81.41
- CDXC 89.66
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.